Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma

CNS Oncol. 2015;4(3):131-5. doi: 10.2217/cns.15.3. Epub 2015 Apr 23.

Abstract

Indolent CNS lymphomas (CNSLs) are rare and no guidelines exist for management. Recent literature highlights the potential for safe and tolerable intrathecal (IT) delivery of rituximab, a large anti-CD20 monoclonal antibody, for aggressive CNSL. We report a patient with relapsed indolent CNSL who failed systemic rituximab and could not tolerate IT chemotherapies, but had an objective response of 6 months duration to IT rituximab.

Keywords: CNS lymphoma; indolent lymphoma; intrathecal rituximab; low-grade lymphoma.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Central Nervous System Neoplasms / cerebrospinal fluid*
  • Central Nervous System Neoplasms / drug therapy*
  • Humans
  • Lymphoma / cerebrospinal fluid*
  • Lymphoma / drug therapy*
  • Male
  • Neoplasm Recurrence, Local
  • Rituximab / therapeutic use*

Substances

  • Antineoplastic Agents
  • Rituximab